Paul N. Knobl

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Pharmacodynamics of Caplacizumab in Healthy Volunteers and Phase 2/3 Trial Patients with Immune-mediated Thrombotic Thrombocytopenic Purpura.

Pharmacodynamics of Caplacizumab in Healthy Volunteers and Phase 2/3 Trial Patients with Immune-mediated Thrombotic Thrombocytopenic Purpura.

Journal: Thrombosis and haemostasis

Published: July 15, 2026

Management of critically ill cancer patients. Expert consensus statement of the "Intensive Care for Hematology and Oncology Patients" (iCHOP) Working Group of the German Society of Hematology and Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN).

Management of critically ill cancer patients. Expert consensus statement of the "Intensive Care for Hematology and Oncology Patients" (iCHOP) Working Group of the German Society of Hematology and Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN).

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 01, 2026

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 20, 2026

Corrigendum to 'Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry': [Journal of Thrombosis and Haemostasis 23(11) (2025) 3569-3577].

Corrigendum to 'Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry': [Journal of Thrombosis and Haemostasis 23(11) (2025) 3569-3577].

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 19, 2025

Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura.

Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura.

Journal: Blood

Published: October 14, 2025

Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura.

Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura.

Journal: Blood

Published: October 14, 2025

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Journal: Blood advances

Published: September 03, 2025

Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.

Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.

Journal: Blood advances

Published: September 03, 2025

Correction: Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.

Correction: Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.

Journal: Intensive care medicine

Published: July 22, 2025

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.

Journal: Blood advances

Published: May 13, 2025

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis.

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis.

Journal: Haematologica

Published: April 24, 2025

Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.

Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.

Journal: Intensive care medicine

Published: March 04, 2025

Showing 1-12 of 108

Last Updated: 09/26/2026